ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
ICD-10-PCS Code Range for Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products is medical classification list by Centers for Medicare and Medicaid Services (CMS).
ICD-10-PCS code range (XW0), contains ICD-10-PCS codes for Nervous System, New Technology, Anatomical Regions, Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
PCS Tables
| X New Technology |
| W Anatomical Regions |
| 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| Body Part | Approach | Device / Substance / Technology | Qualifier |
|---|---|---|---|
| Character 4 | Character 5 | Character 6 | Character 7 |
Body System (Character 4)
0 Skin | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Daratumumab and Hyaluronidase-fihj | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Talquetamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 4 Teclistamab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Satralizumab-mwge | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal AntibodyH Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Elranatamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1 | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Epcoritamab Monoclonal Antibody | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T COVID-19 Vaccine Dose 2U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3 | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) 3 Percutaneous | Substance (Character 6) W COVID-19 Vaccine Booster | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
1 Subcutaneous Tissue | Approach (Character 5) X External | Substance (Character 6) 2 Anacaulase-bcdb | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
2 Muscle | Approach (Character 5) 0 Open | Substance (Character 6) D Engineered Allogeneic Thymus Tissue | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S COVID-19 Vaccine Dose 1T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
2 Muscle | Approach (Character 5) 3 Percutaneous | Substance (Character 6) V COVID-19 Vaccine Dose 3W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
3 Peripheral Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Brexanolone | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 0 Spesolimab Monoclonal Antibody | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 2 Nerinitide3 Durvalumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Narsoplimab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 5 Mosunetuzumab Antineoplastic | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Terlipressin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 6 Afamitresgene Autoleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Coagulation Factor Xa, Inactivated | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Trilaciclib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 7 Tabelecleucel Immunotherapy | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Lurbinectedin | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 8 Treosulfan | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Ceftolozane/Tazobactam Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 9 Inebilizumab-cdon | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Cefiderocol Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) A Ciltacabtagene Autoleucel | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Cytarabine and Daunorubicin Liposome Antineoplastic | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Omadacycline Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) B Amivantamab Monoclonal Antibody | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Eculizumab | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) D Atezolizumab Antineoplastic | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Remdesivir Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) E Etesevimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 3 New Technology Group 3 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Other New Technology Therapeutic Substance | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) F Bamlanivimab Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Sarilumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G REGN-COV2 Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Tocilizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Other New Technology Monoclonal Antibody | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) H Axicabtagene Ciloleucel ImmunotherapyJ Tisagenlecleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Fosfomycin Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Idecabtagene Vicleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) K Sulbactam-Durlobactam | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L CD24Fc Immunomodulator | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) L Lifileucel ImmunotherapyM Brexucabtagene Autoleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Meropenem-vaborbactam Anti-infective | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) N Lisocabtagene Maraleucel Immunotherapy | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) P Glofitamab Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q Tagraxofusp-erzs Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) Q PosoleucelR Rezafungin | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
4 Central Vein | Approach (Character 5) 3 Percutaneous | Substance (Character 6) S Iobenguane I-131 AntineoplasticU Imipenem-cilastatin-relebactam Anti-infective W Caplacizumab | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
5 Peripheral Artery | Approach (Character 5) 3 Percutaneous | Substance (Character 6) T Melphalan Hydrochloride Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
9 Nose | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Esketamine Hydrochloride | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 3 Maribavir Anti-infective | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 6 Lefamulin Anti-infective | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) 8 Uridine Triacetate | Qualifier (Character 7) 2 New Technology Group 2 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) F Other New Technology Therapeutic SubstanceJ Apalutamide Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) J Quizartinib Antineoplastic | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) K Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) L Erdafitinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) N SER-109 | Qualifier (Character 7) 9 New Technology Group 9 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Venetoclax Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
D Mouth and Pharynx | Approach (Character 5) X External | Substance (Character 6) T RuxolitinibV Gilteritinib Antineoplastic | Qualifier (Character 7) 5 New Technology Group 5 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
G Upper GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
G Upper GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) 3 Maribavir Anti-infectiveK Sabizabulin | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) M Baricitinib | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) R Fostamatinib | Qualifier (Character 7) 7 New Technology Group 7 | Body System (Character 4)
H Lower GI | Approach (Character 5) 7 Via Natural or Artificial Opening | Substance (Character 6) X Broad Consortium Microbiota-based Live Biotherapeutic Suspension | Qualifier (Character 7) 8 New Technology Group 8 | Body System (Character 4)
H Lower GI | Approach (Character 5) 8 Via Natural or Artificial Opening Endoscopic | Substance (Character 6) 8 Mineral-based Topical Hemostatic Agent | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
Q Cranial Cavity and Brain | Approach (Character 5) 3 Percutaneous | Substance (Character 6) 1 Eladocagene exuparvovec | Qualifier (Character 7) 6 New Technology Group 6 | Body System (Character 4)
V Bones | Approach (Character 5) 0 Open | Substance (Character 6) P Antibiotic-eluting Bone Void Filler | Qualifier (Character 7) 7 New Technology Group 7 |